Skip to main content
. Author manuscript; available in PMC: 2023 Aug 9.
Published in final edited form as: Hepatology. 2023 Feb 20;78(1):243–257. doi: 10.1097/HEP.0000000000000307

Figure 8: Working Model:

Figure 8:

p16 expression in cholangiocytes and hepatocytes increases following HFD. Increased p16 in hepatocytes results in elevated uptake of long chain fatty acids via FABP1 and increased fat oxidation. Increased p16 in cholangiocytes results in elevated IGF-1 production via upregulation of the E2F1/FOXO1 axis. p16 VM injection reduces p16 expression in both hepatocytes and cholangiocytes leading to a marked reduction in NAFLD phenotypes and downregulation of E2F1/FOXO1/IGF-1 in cholangiocytes. Image produced by BioRender.com.